Dr Stock Pick HOT News & Alerts!
_________________________________________
FREE Daily Stock Alerts From DrStockPick.com
_________________________________________
Monday October 19, 2009
DrStockPick.com Stock Report!
PFE, PWRM, BIIB
PWRM, Power 3 Medical Products Inc, PWRM.OB
Power3 Medical Products, Inc. is a leading bio-medical company engaged in the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3�s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 expects to complete phase II clinical validation trials of its blood serum diagnostics for Alzheimer�s disease (NuroPro-AD), and Parkinson�s disease (NuroPro-PD) in 2009 and for breast cancer in 2010, followed by filings with the FDA. Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas. Power3 continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer�s, and Parkinson�s diseases, and breast cancer.
PWRM Announced that its Chief Scientific Officer is Ch! air and Keynote Speaker of Session at the BTI Life Sciences 2nd Annual Congress and Expo of Molecular Diagnostics in Beijing, China in November 2009
Further international recognition of validity as the company�s President and CSO, Dr. Ira Goldknopf will deliver an invited Keynote address and chair a session on �Biomarkers and Diagnostics in Personalized Medicine (Track 6-4),� at the BIT Life Sciences 2nd International Congress and Expo of Molecular Diagnostics in Beijing, China, November 19-21, 2009. The Theme of the meeting is �New Leadership of Personalized Medicine.�
More about PWRM at www.power3medical.com
PFE, Pfizer Inc
PFE engages in the discovery, development, manufacture, and marketing of prescription medicines for humans and animals worldwide.
PFE announced that 24-week data from two clinical studies of the oral JAK inhibitor, CP-690,550, confirmed statistically significant ACR20 response and DAS28 remission rates for several doses versus placebo when given alone or in combination with methotrexate for patients with active rheumatoid arthritis (RA). The findings, which were presented this week at the 2009 ACR/ARHP Annual Scientific Meeting in Philadelphia, represent the final analyses from two Phase 2 trials evaluating the effect of CP-690,550 over 24 weeks.
BIIB, Biogen Idec Inc.
BIIB creates new standards of care in therapeutic areas with high unmet medical needs. BIIB is a global leader in the discovery, development, manufacturing, and commercialization of innovative therapies. Patients in more than 90 countries benefit from Biogen Idec’s significant products that address diseases such as lymphoma, multiple sclerosis, and rheumatoid arthritis.
BIIB and Biovitrum AB today announced that they plan to advance the companies� long-acting, fully-recombinant Factor IX Fc fusion protein (rFIXFc) into a registrational clinical trial in h! emophili a B patients. The decision to advance the program is based on promising data from a Phase I/IIa open-label, multi-center, safety dose-escalation and pharmacokinetic study of intravenous rFIXFc in severe, previously-treated hemophilia B patients. rFIXFc was well tolerated in the study. In addition, rFIXFc demonstrated a prolonged half-life compared to historical data for existing therapies, supporting advancement of the program.
Keep a close eye on PWRM, PFE and BIIB, do your homework, and like always BE READY for the ACTION!
Related Articles:Fears Fuel Rise in Oil Prices
Best Wall St. Stocks Today: TTHI,ELY
Tags: 2013 Silver Stocks ,Best Stocks For 2013 ,Best Stocks To Invest In 2013 ,Best Stocks To Watch For 2013 ,Top Dividend Stocks 2012
No comments:
Post a Comment